Pharmafile Logo

News and Press Releases

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Financing led by Investissement Québec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients. 10 February 2026 -- Montreal,...

Category: Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT

20 January 2026 -- Heidelberg, Germany -- Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m)...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Exciva
info@exciva.com
Hauptstrasse 25, 69117 Heidelberg, Germany

CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform

Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development 24 April 2025 -- Cambridge, UK -- CN Bio,...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan

Agreement establishes direct distribution channel for customers in Japan, providing local support and expertise Partnership solidifies CN Bio’s presence in Asian markets and supports ongoing global expansion. 14 January 2025...

Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: January 14, 2025

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan...

Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024

Phoremost Ltd
info@phoremost.com
PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom

Epsilogen completes £12.5 million Series B financing expansion

Expansion brings total Series B funds raised to £43.25 million Proceeds to support the delivery of clinical Proof of Concept for MOv18 IgE 9 September 2024 -- London, UK --...

Category: Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2024

Epsilogen
info@epsilogen.com
Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team

Key appointment to support continued UK and US team expansion 27 June 2024 -- Cambridge, UK -- CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced...

Category: Biotechnology, Other, Pharmaceutical
Posted: June 27, 2024

CN Bio
332 Cambridge Science Park, Milton Road Cambridge, CB4 0WN

CN Bio raises $21m in first close of Series B investment round

Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10m and $5.5m, respectively Investment will expand product development and scaling of the organisation to meet increased demand for...

Category: Biotechnology, Drug Discovery, Other
Posted: April 23, 2024

CN Bio
332 Cambridge Science Park, Milton Road Cambridge, CB4 0WN

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies 

Strategic partnership harnesses respective organ-specific expertise to provide complete human-derived Organ-on-a-Chip solution for more accurate in vitro ADME predictions   Early access to dual-organ model available through CN Bio’s Contract Research...

Category: Biotechnology
Posted: January 23, 2024

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry 23 November 2023 -- Cambridge, UK --...

Category: Clinical Trials
Posted: November 23, 2023

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ